Intranasal Lidocaine for Treatment of Migraine A

Authors: Morris Maizels Barbara Scott Wendy Cohen Wansu Chen

Publish Date: 1996/07/24

Volume: 276, Issue: 4, Pages: 319-321

PDF Link

Abstract

Patients  —A total of 81 patients 67 women and 14 men median age 42 years range 1968 years with a chief complaint of headache who fulfilled criteria of the International Headache Society for migraine participated Patients were excluded if headache had lasted more than 3 days or if the frequency of severe headache was more than once per weekMain Outcome Measures  —The primary outcome measure was at least 50 reduction of headache within 15 minutes after treatment Secondary measures include reduction in nausea and photophobia use of rescue medication relapse of headache and change in headache disability scoresResults  —Of 53 patients who received intranasal lidocaine 29 55 had at least a 50 reduction of headache compared with 6 21 of 28 controls P=004 Nausea and photophobia were significantly reduced P=03 and P=001 respectively Rescue medication for headache relief was needed in 15 28 of 53 patients in the lidocaine group vs 20 71 of 28 controls P001 Among those with initial relief of headache relapse of headache occurred in 10 42 of 24 in the lidocaine group vs 5 83 of 6 in the control group P=17 usually within the first hour after treatment

Keywords: